Zobrazeno 1 - 10
of 333
pro vyhledávání: '"Roberto M Lemoli"'
Autor:
Raffaele Palmieri, Atto Billio, Felicetto Ferrara, Sara Galimberti, Roberto M. Lemoli, Elisabetta Todisco, Federico Moretti, Adriano Venditti
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
In patients with Acute Myeloid Leukemia (AML), the assessment of disease risk plays a central role in the era of personalized medicine. Indeed, integrating baseline clinical and biological features on a case-by-case basis is not only essential to sel
Externí odkaz:
https://doaj.org/article/04809ebf7d18461cb71b1d71159b3eda
Autor:
Roberto M Lemoli, Alessandra D'Addio
Publikováno v:
Revista Brasileira de Hematologia e Hemoterapia, Vol 33, Iss 3, Pp 172-173 (2011)
Externí odkaz:
https://doaj.org/article/89afaa20be12483e85405afa5162bae6
Autor:
Francesca Palandri, Elena M. Elli, Giuseppe Auteri, Massimiliano Bonifacio, Giulia Benevolo, Florian H. Heidel, Simona Paglia, Malgorzata M. Trawinska, Costanza Bosi, Elena Rossi, Mario Tiribelli, Alessia Tieghi, Alessandra Iurlo, Nicola Polverelli, Giovanni Caocci, Gianni Binotto, Francesco Cavazzini, Eloise Beggiato, Daniela Cilloni, Caterina Tatarelli, Francesco Mendicino, Maurizio Miglino, Monica Bocchia, Monica Crugnola, Camilla Mazzoni, Andrea D. Romagnoli, Giovanni Rindone, Sara Ceglie, Alessandra D’Addio, Eleonora Santoni, Daniele Cattaneo, Daniela Bartoletti, Roberto M. Lemoli, Mauro Krampera, Antonio Cuneo, Gianpietro C. Semenzato, Roberto Latagliata, Elisabetta Abruzzese, Nicola Vianelli, Michele Cavo, Alessandro Andriani, Valerio De Stefano, Giuseppe A. Palumbo, Massimo Breccia
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-5 (2023)
Externí odkaz:
https://doaj.org/article/142637191ad84c61a603c3e424c76be2
Autor:
Pasquale Esposito, Daniela Picciotto, Francesca Costigliolo, Elisa Russo, Lucia Macciò, Giovanna Cenacchi, Antonia Cagnetta, Michele Cea, Roberto M. Lemoli, Francesca Viazzi
Publikováno v:
Frontiers in Medicine, Vol 10 (2023)
Although rare, C3 glomerulopathy (C3G) is increasingly recognized thanks to the currently available diagnostic skills. C3G is not a single disease but a group of disorders with distinct pathogenesis and progression. Thus, an essential step for its ma
Externí odkaz:
https://doaj.org/article/19f127f16b244722b894407743ebcdfc
Autor:
Fabio Efficace, Laura Cannella, Xavier Thomas, Meltem Kurt Yüksel, Silvia Maria Trisolini, Alberto Brini, Ernesta Audisio, Luca Maurillo, Roberto M. Lemoli, Annalisa Imovilli, Irina Panovska-Stavridis, Livio Pagano, Maria Ciccone, Nunzio Filardi, Nicola Stefano Fracchiolla, Daniele Vallisa, Monica Crugnola, Nicola Cascavilla, Matevz Skerget, Marco Vignetti, Frederic Baron, On Behalf of the Gimema and Eortc Leukemia and Quality of Life Groups
Publikováno v:
HemaSphere, Vol 7, p e90211c0 (2023)
Externí odkaz:
https://doaj.org/article/1c2b993187f2494ab0ad977e17937429
Autor:
Francesca Palandri, Giuseppe A. Palumbo, Massimiliano Bonifacio, Elena M. Elli, Mario Tiribelli, Giuseppe Auteri, Malgorzata M. Trawinska, Nicola Polverelli, Giulia Benevolo, Alessia Tieghi, Fabrizio Cavalca, Giovanni Caocci, Eloise Beggiato, Gianni Binotto, Francesco Cavazzini, Maurizio Miglino, Costanza Bosi, Monica Crugnola, Monica Bocchia, Bruno Martino, Novella Pugliese, Marta Venturi, Alessandro Isidori, Daniele Cattaneo, Mauro Krampera, Fabrizio Pane, Daniela Cilloni, Gianpietro Semenzato, Roberto M. Lemoli, Antonio Cuneo, Elisabetta Abruzzese, Filippo Branzanti, Nicola Vianelli, Michele Cavo, Florian Heidel, Alessandra Iurlo, Massimo Breccia
Publikováno v:
Cancers, Vol 15, Iss 20, p 5027 (2023)
Most patients with myelofibrosis (MF) discontinue ruxolitinib (JAK1/JAK2 inhibitor) in the first 5 years of therapy due to therapy failure. As the therapeutic possibilities of MF are expanding, it is critical to identify patients predisposed to early
Externí odkaz:
https://doaj.org/article/3b1b3d2c637c42db8dbfdc313c7dde15
Autor:
Raffaella Meazza, Loredana Ruggeri, Fabio Guolo, Paola Minetto, Paolo Canevali, Fabrizio Loiacono, Sara Ciardelli, Alessandra Bo, Silvia Luchetti, Alberto Serio, Letizia Zannoni, Christelle Retière, Natalia Colomar-Carando, Sarah Parisi, Antonio Curti, Roberto M. Lemoli, Daniela Pende
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Natural killer (NK) cell-based adoptive immunotherapy in leukemia patients is an emerging field of interest based on clinical evidence of efficacy and safety. Elderly acute myeloid leukemia (AML) patients have been successfully treated with NK cells
Externí odkaz:
https://doaj.org/article/7806e75dcd254c8181d3f1c13ffaebba
Autor:
Cristiana Lavazza, Silvia Budelli, Elisa Montelatici, Mariele Viganò, Francesca Ulbar, Lucia Catani, Marta Giulia Cannone, Sara Savelli, Elisa Groppelli, Lorenza Lazzari, Roberto M. Lemoli, Matteo Cescon, Gaetano La Manna, Rosaria Giordano, Tiziana Montemurro
Publikováno v:
Journal of Translational Medicine, Vol 20, Iss 1, Pp 1-21 (2022)
Abstract Background A growing number of clinical trials have shown that regulatory T (Treg) cell transfer may have a favorable effect on the maintenance of self-tolerance and immune homeostasis in different conditions such as graft-versus-host diseas
Externí odkaz:
https://doaj.org/article/3b6c78ae2c5f423586ff3cf27b6325ba
Autor:
Francesca Palandri, Elena Rossi, Giuseppe Auteri, Massimo Breccia, Simona Paglia, Giulia Benevolo, Elena M. Elli, Francesco Cavazzini, Gianni Binotto, Alessia Tieghi, Mario Tiribelli, Florian H. Heidel, Massimiliano Bonifacio, Novella Pugliese, Giovanni Caocci, Monica Crugnola, Francesco Mendicino, Alessandra D'Addio, Simona Tomassetti, Bruno Martino, Nicola Polverelli, Sara Ceglie, Camilla Mazzoni, Rikard Mullai, Alessia Ripamonti, Bruno Garibaldi, Fabrizio Pane, Antonio Cuneo, Mauro Krampera, Gianpietro Semenzato, Roberto M. Lemoli, Nicola Vianelli, Giuseppe A. Palumbo, Alessandro Andriani, Michele Cavo, Roberto Latagliata, Valerio De Stefano
Publikováno v:
Cancers, Vol 15, Iss 14, p 3706 (2023)
In polycythemia vera (PV), the prognostic relevance of an ELN-defined complete response (CR) to hydroxyurea (HU), the predictors of response, and patients’ triggers for switching to ruxolitinib are uncertain. In a real-world analysis, we evaluated
Externí odkaz:
https://doaj.org/article/8d4eada01d2347b88c75af18035a8758
Autor:
Michele Malagola, Alessandra Iurlo, Elisabetta Abruzzese, Massimiliano Bonifacio, Fabio Stagno, Gianni Binotto, Mariella D’Adda, Monia Lunghi, Monica Crugnola, Maria Luisa Ferrari, Francesca Lunghi, Fausto Castagnetti, Gianantonio Rosti, Roberto M. Lemoli, Rosaria Sancetta, Maria Rosaria Coppi, Maria Teresa Corsetti, Giovanna Rege Cambrin, Atelda Romano, Mario Tiribelli, Antonella Russo Rossi, Sabina Russo, Lara Aprile, Monica Bocchia, Lisa Gandolfi, Mirko Farina, Simona Bernardi, Nicola Polverelli, Aldo M. Roccaro, Antonio De Vivo, Michele Baccarani, Domenico Russo
Publikováno v:
Cancer Medicine, Vol 10, Iss 5, Pp 1726-1737 (2021)
Abstract Background Intermittent treatment with TKIs is an option for the great majority (70%–80%) of CML patients who do not achieve a stable deep molecular response and are not eligible for treatment discontinuation. For these patients, the only
Externí odkaz:
https://doaj.org/article/b182193348604dd0987cace12205f347